Press release
Illumina® Protein Prep launches to drive greater proteomic insights for improved drug discovery and development
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of
About this update from Illumina, Inc.
[{"type":"text","content":"Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease \nFollowing early access program, customers commend scale, high consistency, and easy sample to insights workflow\nLaunch follows Illumina's announcement of agreement to acquire SomaLogic\nSAN DIEGO, Sept. 3, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale. Illumina Protein Prep has been available through an early-access program, and is now broadly available to customers worldwide, enabling researchers to add proteomics to large-scale genomics studies and fuel new insights across cancer and cardio metabolic and immunologic diseases, with a streamlined sample-to-insights solution for discovery and clinical research. \n\n \n \n\n \n\"NGS-based proteomics provides critical speed, accuracy, reproducibility, and scalability to power large studies and accelerate the drug discovery pipeline for our ecosystem partners in biopharma,\" said Steve Barnard, chief technology officer of Illumina. \"Proteomics is essential to advancing our understanding of disease and is a central pillar of multiomics. Illumina Protein Prep will help deliver multiomics at scale to transform biologic discovery.\"\nProteomics offers a view into proteins and their functions in biologic processes. Understanding their roles in gene expression and how proteins change throughout disease states is critical to biomarker discovery and precision therapy development. Illumina Protein Prep is powered by SOMAmer™ technology and can measure 9500 unique human protein targets, the most with an NGS readout; offering the greatest insights into protein biology.\nCombining Illumina Protein Prep with the power and scalability of Illumina NovaSeq™ sequencing platforms enables the simultaneous interrogation of thousands of proteins in a single experiment, maximizing the discovery power of proteomics studies. After sequencing, Illumina DRAGEN™ Protein Quantification and Connected Multiomics software work together to turn complex proteomic data into clear insights. This powerful combination helps researchers streamline analysis and accelerate progress from disc...